. Author manuscript; available in PMC: 2020 Mar 5.

Published in final edited form as: Dig Dis Sci. 2019 Mar 5;64(6):1651–1659. doi: 10.1007/s10620-019-05570-1

Table 3.

Correlation between serum vedolizumab levels at different time points and baseline (week 0) biomarkers

Biomarker at baseline (week 0)	C-reactive protein	Serum albumin	Fecal calprotectin
Vedolizumab levels weeks 2 [rho (p value)]	−0.27 (0.05)	0.23 (0.1)	−0.43 (0.002^*)
Vedolizumab levels weeks 6 [rho (p value)]	−0.23 (0.09)	0.39 (0.003^*)	−0.31 (0.03^*)
Vedolizumab levels weeks 14 [rho (p value)]	−0.28 (0.042^*)	0.3 (0.027^*)	−0.26 (0.08)
Vedolizumab levels weeks 22 [r² (p value)]	−0.22 (0.17)	0.33 (0.031^*)	−0.27 (0.113)
Vedolizumab levels weeks 30 [r² (p value)]	−0.16 (0.43)	0.46 (0.02^*)	−0.41 (0.05)

Statistically significant